Galecto is a Danish drug development company based in Copenhagen. Galecto focuses on small molecule therapeutics directed at biological targets involved in development of fibrotic diseases. The lead program GB0139 is indicated for the treatment of idiopathic pulmonary fibrosis and is currently in phase 2b clinical testing.

Year of investment
2020

Sector
Drug development

Location
Copenhagen, Denmark

Website
https://galecto.com/

Leave a Reply

Your email address will not be published. Required fields are marked *